The company released a statement on Monday, saying “We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 Ensemble trial, due to an unexplained illness in a study participant.”
The study aimed to test 60,000 participants across the US, Argentina, Brazil and several other countries.
In September, pharmaceutical company AstraZeneca paused clinical trials of an experimental COVID-19 vaccine after a participant in the UK had an unexplained illness, but the study has since resumed in the country.
Johnson & Johnson is in the third and final stage of its trial.
